Ozempic, Wegovy, Mounjaro, Rybelsus or Saxenda: what's the difference
Ozempic has become one of the best-known medicines for weight loss, but it is far from the most suitable option for everyone. Side effects, medical reasons, or simply a preference for not using injections often play a role in the choice. Fortunately, several well-researched alternatives are available, such as Wegovy, Mounjaro, Saxenda, and an oral (tablet) option.
Below, we compare the main options based on clinical studies and real-world data (as of March 2026). The average weight losses are indicative and apply when used with diet and exercise; individual results will vary.
Wegovy: higher dose semaglutide, specially for weight loss
Wegovy contains the same active ingredient as Ozempic (semaglutide), but in a higher maximum dose of 2.4 mg per week (injection). Semaglutide mimics GLP-1 in the body, which suppresses appetite. In a large, randomised study published in The New England Journal of Medicine, participants lost an average of approximately 15% of their body weight after 68 weeks, in combination with lifestyle interventions. Recent comparisons and real-world data show that Wegovy is often even around 17% weight loss Deliver.
Mounjaro
Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, providing a more potent appetite suppressant and better effects on blood sugar and fat burning. In the SURMOUNT studies, participants lost on average 20–22% of their body weight, depending on the dose (up to 15 mg). This currently makes Mounjaro one of the most effective options among the available treatments for pure weight loss.
Saxenda
Saxenda contains liraglutide, which also mimics GLP-1 in the body and is injected daily. Research has shown an average weight loss of 5-10%. Although the effect is less pronounced than with newer drugs, it works well for people seeking a proven option with less severe gastrointestinal side effects in some individuals.
Oral options: pills if you don't want an injection For those who wish to avoid injections, alternatives are now available.
- Rybelsus: oral semaglutide
Rybelsus is the tablet form of semaglutide (taken once daily on an empty stomach). It is approved for type 2 diabetes, but is often used off-label for weight loss. Studies and real-world data show an average weight loss of approximately 5–10%. It is a convenient, needle-free option.
Lifestyle always remains the foundation These medicines work best in conjunction with a healthy diet, calorie awareness, and exercise. Research shows that the combination of medication and lifestyle yields significantly more than lifestyle alone – and it also helps to maintain the results for longer.
Which is the best choice? There's no one-size-fits-all. At Wellumo, our doctors will help you choose the best option based on your health, goals, and preferences after a medical intake. You will receive a personalised Bespoke plan, ongoing monitoring and coaching. This is how you make a safe, responsible start and maximise the chance of a sustainable result.
Sources
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36.
Pi-Sunyer X, et al. A Randomised, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.
Toliver JC, et al. Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application. Adv Ther. 2025;42(10):5010-5022.